Literature DB >> 12763508

Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis.

Mark H Wilcox1.   

Abstract

Clostridium difficile causes a spectrum of diseases ranging from diarrhoea to pseudomembranous colitis, primarily in the hospitalized elderly, although community-acquired infection is probably under-documented. Host factors are increasingly recognized as critical determinants of disease expression. Exposure to antibiotics, particularly those adversely affecting anaerobic gut flora, appears to create a niche which is exploited by C. difficile. Several retrospective and intervention studies have indicated that third-generation cephalosporins have a high propensity to induce C. difficile diarrhoea. Conversely, some broad-spectrum antibiotics, including ureidopenicillins (e.g. piperacillin-tazobactam) and ciprofloxacin, are less likely to induce C. difficile infection. Effective control of C. difficile in the hospital requires both antibiotic control and prevention of environmental seeding and bacterial spread. Epidemic C. difficile strains are widely distributed in the hospital environment, both as a cause and result of nosocomial diarrhoea. Current treatment options are antibiotic-based, which is less than ideal. Although many biotherapeutic approaches have been tried few have shown real benefit.

Entities:  

Mesh:

Year:  2003        PMID: 12763508     DOI: 10.1016/s1521-6918(03)00017-9

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  19 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge.

Authors:  M F De La Cochetière; T Durand; P Lepage; A Bourreille; J P Galmiche; J Doré
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

Review 3.  Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Hans C Arora; Charis Eng; Daniel A Shoskes
Journal:  Ann Transl Med       Date:  2017-01

4.  Structure of bacterial transcription factor SpoIIID and evidence for a novel mode of DNA binding.

Authors:  Bin Chen; Paul Himes; Yu Liu; Yang Zhang; Zhenwei Lu; Aizhuo Liu; Honggao Yan; Lee Kroos
Journal:  J Bacteriol       Date:  2014-02-28       Impact factor: 3.490

Review 5.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

6.  Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil.

Authors:  Rafael Morales Chamorro; Raquel Serrano Blanch; María José Méndez Vidal; María Auxiliadora Gómez España; María Jesús Rubio Pérez; Juan Rafael de la Haba Rodríguez; Enrique Aranda Aguilar
Journal:  Clin Transl Oncol       Date:  2005-07       Impact factor: 3.405

7.  Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study.

Authors:  Seema U Nayak; J McLeod Griffiss; Jeffrey Blumer; Mary Ann O'Riordan; Wesley Gray; Robin McKenzie; Robert A Jurao; Amanda T An; Melissa Le; Stacie J Bell; Urs A Ochsner; Thale C Jarvis; Nebojsa Janjic; Jonathan M Zenilman
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

8.  Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Anna Maria Dionisi; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2010-06-16       Impact factor: 5.948

9.  Low risk of irritable bowel syndrome after Clostridium difficile infection.

Authors:  T Piche; G Vanbiervliet; F Girard Pipau; R Dainese; X Hébuterne; P Rampal; S M Collins
Journal:  Can J Gastroenterol       Date:  2007-11       Impact factor: 3.522

10.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.

Authors:  Sandra Dial; Khalid Alrasadi; Chantal Manoukian; Allen Huang; Dick Menzies
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.